US 11,938,113 B2
Epigallocathechin gallate solution
Bernard Do, Issy-les-Moulineaux (FR); Muriel Paul, Montevrain (FR); and Alain Astier, Paris (FR)
Assigned to ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris (FR); and UNIVERSITE PARIS-SACLAY, Gif-sur-Yvette (FR)
Appl. No. 16/766,175
Filed by ASSISTANCE PUBLIQUE—HOPITAUX DE PARIS, Paris (FR); and UNIVERSITE PARIS-SACLAY, Gif-sur-Yvette (FR)
PCT Filed Nov. 21, 2018, PCT No. PCT/EP2018/082029
§ 371(c)(1), (2) Date May 21, 2020,
PCT Pub. No. WO2019/101777, PCT Pub. Date May 31, 2019.
Claims priority of application No. 17306623 (EP), filed on Nov. 23, 2017.
Prior Publication US 2020/0375939 A1, Dec. 3, 2020
Int. Cl. A61K 31/352 (2006.01); A61K 8/362 (2006.01); A61K 8/49 (2006.01); A61K 8/60 (2006.01); A61K 47/12 (2006.01); A61K 47/26 (2006.01); A61Q 19/00 (2006.01)
CPC A61K 31/352 (2013.01) [A61K 8/362 (2013.01); A61K 8/498 (2013.01); A61K 8/60 (2013.01); A61K 47/12 (2013.01); A61K 47/26 (2013.01); A61Q 19/00 (2013.01)] 16 Claims
 
1. A stable pharmaceutical or dermo-cosmetic aqueous solution comprising:
13-107 mg/ml of epigallocatechin gallate,
at least one disaccharide,
0.1-1.0 mmol/l of at least one chelating agent,
a pharmaceutically acceptable or dermo-cosmetically acceptable pH-modifying agent, and
wherein said solution is at a pH in a range of 3.0 to 4.0 and the molar ratio of epigallocatechin gallate/disaccharide is from 0.1 to 0.8.